These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17877460)

  • 1. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
    Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
    Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
    Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
    Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the kinetic properties of the lipid- and protein-kinase activities of the p110alpha and p110beta catalytic subunits of class-Ia phosphoinositide 3-kinases.
    Beeton CA; Chance EM; Foukas LC; Shepherd PR
    Biochem J; 2000 Sep; 350 Pt 2(Pt 2):353-9. PubMed ID: 10947948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional differences between two classes of oncogenic mutation in the PIK3CA gene.
    Chaussade C; Cho K; Mawson C; Rewcastle GW; Shepherd PR
    Biochem Biophys Res Commun; 2009 Apr; 381(4):577-81. PubMed ID: 19233141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new evaluation method for quantifying PI3K activity by HTRF assay.
    Sugita H; Dan S; Kong D; Tomida A; Yamori T
    Biochem Biophys Res Commun; 2008 Dec; 377(3):941-5. PubMed ID: 18952065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
    Riener MO; Bawohl M; Clavien PA; Jochum W
    Genes Chromosomes Cancer; 2008 May; 47(5):363-7. PubMed ID: 18181165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.
    Chaudhari A; Krumlinde D; Lundqvist A; Akyürek LM; Bandaru S; Skålén K; Ståhlman M; Borén J; Wettergren Y; Ejeskär K; Rotter Sopasakis V
    Mol Cell Biol; 2015 Oct; 35(19):3258-73. PubMed ID: 26169833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
    Vogt PK; Bader AG; Kang S
    Virology; 2006 Jan; 344(1):131-8. PubMed ID: 16364744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
    Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
    Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic PI3K deregulates transcription and translation.
    Bader AG; Kang S; Zhao L; Vogt PK
    Nat Rev Cancer; 2005 Dec; 5(12):921-9. PubMed ID: 16341083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
    Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. eIF4E binding protein 1 and H-Ras are novel substrates for the protein kinase activity of class-I phosphoinositide 3-kinase.
    Foukas LC; Shepherd PR
    Biochem Biophys Res Commun; 2004 Jun; 319(2):541-9. PubMed ID: 15178440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.
    Meier TI; Cook JA; Thomas JE; Radding JA; Horn C; Lingaraj T; Smith MC
    Protein Expr Purif; 2004 Jun; 35(2):218-24. PubMed ID: 15135396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SH3 domain of the phosphatidylinositol 3-kinase regulatory subunit is responsible for the formation of a sequestration complex with insulin receptor substrate-1.
    Ikegami Y; Inukai K; Awata T; Asano T; Katayama S
    Biochem Biophys Res Commun; 2008 Jan; 365(3):433-8. PubMed ID: 17991427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
    Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
    Bader AG; Kang S; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.